SHANGHAI, June 16, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, today announced the cooperation in physician education with AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. ("AbbVie Shanghai"), a subsidiary of AbbVie Inc (NYSE: ABBV) ("AbbVie"). AbbVie is a research-based global biopharmaceutical company. Pursuant to an agreement to facilitate such cooperation, Zhongchao and AbbVie Shanghai will cooperate in, including but not limited to, developing the medical education contents and producing medical education courses.
SHANGHAI, June 3, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, announced the on-going one-year joint project of leukemia diagnosis and treatment courses (the "Project") that the Company has been hosting with Beijing Bethune Charitable Foundation ("Bethune Foundation") and BeiGene Pharmaceutical (Shanghai) Co., Ltd. ("BeiGene Shanghai"), a subsidiary of BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) ("BeiGene").
SHANGHAI, May 28, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, announced the launch of the patient management service focusing on the professional field of tumor and rare disease operated through its subsidiary Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin").
Revenues and operating income grew 20.9% and 23.3%, respectively SHANGHAI, April 30, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced its financial results for the fiscal year ended December 31, 2020.
SHANGHAI, Mar. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program "Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals" (“PAH Project”) in 2021. The PAH Project aims to promote the implementation of the multidisciplinary treatment model of pulmonary hypertension and improve doctors ability to solve clinical problems. In 2020, more than 200 experts in pulmonary hypertension participated in the PAH Project, training a total of 10,000 clinicians. In 2021, we expect increased clinicians to participate in PHA Project to get training for knowledge updates, skill learning, and experience exchange in pulmonary hypertension. Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "Compared to the population base and the number of potential pulmonary hypertension patients in China, the number of physicians specializing in the diagnosis and treatment of this field is very limited. Therefore, our PAH project in 2020 had received positive response and recognition from the majority of clinicians. The success of the PAH project brings valuable experiences for us in educating rare diseases. We believe we will attract more social and commercial cooperation in promoting rare diseases education to grow our business further.”
Shanghai, China, Jan. 13, 2021 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it co-sponsored the National Annual Conference for Standardized Liver Cancer Diagnosis and Treatment (the “Annual Conference”) with China Association of Health Promotion and Education and Chinese Society of Liver Cancer.
Shanghai, China, November 12, 2020 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that the Company and Takeda Pharmaceutical Company Limited (“Takeda”) agreed to expand their current scope of cooperation which now covers five of Takeda’s subsidiaries in China including the new addition of Baishen Biotechnology (Shanghai) Co., Ltd. Pursuant to the amended service agreement by and between Zhongchao and Takeda, Zhongchao shall continue to serve as Takeda’s vendor and partner in China, providing a broad range of services in medical editing, document collation, and medical training and education to Takeda.
Shanghai, China, September 21, 2020 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced its unaudited financial results for the six months ended June 30, 2020.
SHANGHAI, Aug. 21, 2020 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it continues to partner with European Wound Management Association ("EWMA") to offer advanced workshops on wound care and rehabilitation (the "Workshops") to physicians. The Workshops cover Wound Management Core Course and Wound Healing Advanced Course, both of which are part of the EWMA Curriculums on Wound Healing for Physicians (the "EWMA Curriculums") and are exclusively licensed to Zhongchao in China. The Workshops are offered on-site only with each session typically taking 5 full days. Upon completion of a workshop session, participants are eligible to take a qualification exam and receive an EWMA certificate.
Shanghai, China, Aug. 11, 2020 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it has partnered with the China Association of Health Promotion and Education (the “CAHPE”) on developing live interactive programs/courses (the “Project”) aiming to promote and implement the Global Initiative for Chronic Obstructive Lung Disease (the “GOLD”) in China.